LinkedIn Image prIME Clinical Updates in Lung Cancer: Critical Analysis and Practical Application of Key Data From the 2016 Annual Lung Cancer Conference in Vienna

prIME Clinical Updates in Lung Cancer: Critical Analysis and Practical Application of Key Data From the 2016 Annual Lung Cancer Conference in Vienna

View Activity

Activity Features

CME-Certified

Expert Discussion

Activity Overview

View video-based expert analysis and summaries of the most essential clinical data presented at the 2016 Lung Cancer Conference in Vienna, covering reports on advances in EGFR-targeted therapy, immunotherapy, and the treatment of ALK-positive NSCLC.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Each module may provide the following credits:

  • Module 1: 0.5
  • Module 2: 0.25
CME and Disclosure Information

Intro

Featured Experts

  • Tony Mok, MD, FRCP, The Chinese University of Hong Kong, Hong Kong, China

Featured Topic

Brief introduction of the topics being discussed

Module 1

Featured Experts

  • Suresh Ramalingam, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
  • Naiyer Rizvi, MD, New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York, United States

Featured Abstracts

Abstract #PL03.03: Randomised phase III study of osimertinib vs platinum-pemetrexed for EGFR T790M-positive advanced NSCLC (AURA3)
Abstract #MA08.03: Osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): Plasma ctDNA analysis
Abstract #PL04a.03: Durvalumab in ≥3rd-line locally advanced or metastatic, EGFR/ALK wild-type NSCLC: Results from the phase 2 ATLANTIC Study
Abstract #MA09.02: Pembrolizumab + carboplatin and pemetrexed as 1st-line therapy for advanced non–small cell lung cancer: KEYNOTE-021 Cohort G
Abstract #OA03.01: First-line nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced NSCLC: Long-term outcomes from CheckMate 012
Abstract #MA09.05: Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and updated analyses from the Checkmate 032 trial

Module 2

Featured Experts

  • Howard L. (Jack) West, MD, Swedish Cancer Institute, Seattle, Washington, United States

Featured Abstracts

Abstract #MA07.03: Alectinib (ALC) versus crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from phase III study (J-ALEX) (ID 5597)
Abstract #PL03.07: First-line ceritinib versus chemotherapy in patients with ALK-rearranged (ALK+) NSCLC: A randomized, phase 3 study (ASCEND-4)
Abstract #P3.02a-013: Brigatinib in crizotinib-refractory ALK+ NSCLC: Central assessment and updates from ALTA, a pivotal randomized phase 2 trial
Abstract #OA08.06: Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials

Featured Experts

  • Suresh Ramalingam, MD, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
  • Naiyer Rizvi, MD, New York-Presbyterian Hospital, Columbia University Medical Center, New York, New York, United States

Featured Abstracts

Abstract #PL03.03: Randomised phase III study of osimertinib vs platinum-pemetrexed for EGFR T790M-positive advanced NSCLC (AURA3)
Abstract #MA08.03: Osimertinib vs platinum-pemetrexed for T790M-mutation positive advanced NSCLC (AURA3): Plasma ctDNA analysis
Abstract #PL04a.03: Durvalumab in ≥3rd-line locally advanced or metastatic, EGFR/ALK wild-type NSCLC: Results from the phase 2 ATLANTIC Study
Abstract #MA09.02: Pembrolizumab + carboplatin and pemetrexed as 1st-line therapy for advanced non–small cell lung cancer: KEYNOTE-021 Cohort G
Abstract #OA03.01: First-line nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced NSCLC: Long-term outcomes from CheckMate 012
Abstract #MA09.05: Nivolumab alone or with ipilimumab in recurrent small cell lung cancer (SCLC): 2-year survival and updated analyses from the Checkmate 032 trial

Featured Experts

  • Howard L. (Jack) West, MD, Swedish Cancer Institute, Seattle, Washington, United States

Featured Abstracts

Abstract #MA07.03: Alectinib (ALC) versus crizotinib (CRZ) in ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from phase III study (J-ALEX) (ID 5597)
Abstract #PL03.07: First-line ceritinib versus chemotherapy in patients with ALK-rearranged (ALK+) NSCLC: A randomized, phase 3 study (ASCEND-4)
Abstract #P3.02a-013: Brigatinib in crizotinib-refractory ALK+ NSCLC: Central assessment and updates from ALTA, a pivotal randomized phase 2 trial
Abstract #OA08.06: Brigatinib activity in patients with ALK+ NSCLC and intracranial CNS metastases in two clinical trials

Support

This educational activity is supported by a grant from ARIAD Pharmaceuticals, Inc; AstraZeneca; and Incyte.